U.S. Software Stock News

Lands' End (LE) has just posted Q3 2026 results with revenue of about $317.5 million and basic EPS of $0.17, putting a clear profit on the board for the quarter. The company has seen quarterly revenue hold around the low $300 million mark over the last few periods, while basic EPS has swung from losses of roughly $0.27 and $0.17 earlier in 2026 to a modest profit this quarter, setting up a story that is increasingly about how much of that top line can translate into sustainable margins. See...

If you are wondering whether Papa John's International at around $40.96 is a quietly mispriced opportunity or a value trap in plain sight, this breakdown is for you. The stock is down about 2.8% over the last week, roughly flat over the past month, and still sitting on a 10.5% slide over the past year and a steep 48.2% drop over three years, which indicates sentiment has been under pressure for a while. Recent headlines have focused on Papa John's ongoing strategy tweaks, from sharpening its...

Mama's Creations (MAMA) just posted its Q3 2026 numbers, with revenue of about $47.3 million, basic EPS of $0.01, and net income of $0.5 million, setting the stage for investors to parse how the growth story is holding up. The company has seen quarterly revenue move from $31.5 million in Q3 2025 to $47.3 million in the latest quarter, while EPS shifted from $0.01 to $0.01 and net income from $0.4 million to $0.5 million, giving a clearer read on how much of the top line is actually making it...

Academy Sports and Outdoors (ASO) has posted its Q3 2026 numbers with revenue of about $1.4 billion and EPS of roughly $1.07, giving investors a fresh read on how demand is holding up across the year. The company has seen revenue move from roughly $1.34 billion in Q3 2025 to about $1.38 billion in Q3 2026, while EPS shifted from around $0.94 to $1.07 over the same period, setting a clear baseline for how the business is tracking through the current cycle as margins do the heavy lifting in the...

Star Group (SGU) closed FY 2025 with fourth quarter revenue of $247.7 million and basic EPS of -$0.84, capping off a volatile year that nevertheless left trailing 12 month EPS at $2.12 on $1.8 billion in revenue and net income of $72.8 million. The company has seen quarterly revenue swing from $488.1 million and EPS of $0.79 in Q1 2025 to a peak of $743.0 million and EPS of $2.13 in Q2, before moderating in the second half as Q3 delivered $305.6 million of revenue and EPS of -$0.48. Against...

Campbell's (CPB) has kicked off Q1 2026 with revenue of $2.7 billion and net income of $194 million, translating to EPS of $0.65 as the company puts another steady quarter on the board. Over the past year, revenue has hovered around the $10.0 billion mark while trailing twelve month EPS has moved from $1.90 to $1.94, giving investors a clearer read on how recent quarters are feeding into overall profitability and margin resilience. See our full analysis for Campbell's. With the headline...

Caleres (CAL) opened Q3 2026 with total revenue of about $790 million and EPS of $0.07, while trailing twelve month revenue stood at roughly $2.7 billion with EPS of $0.52, setting a cautious tone around profitability. The company has seen revenue move from $741 million and EPS of $1.20 in Q3 2025 to $790 million and EPS of $0.07 in Q3 2026, a shift that leaves investors watching how much of the story is about topline resilience versus pressure further down the income statement. With net...

AutoZone (AZO) opened fiscal Q1 2026 with total revenue of $4.6 billion and basic EPS of $31.88, setting the stage against a backdrop where trailing twelve month revenue sits at $19.3 billion and EPS at $147.34. Over recent quarters the company has seen revenue move from $6.2 billion in Q4 2024 to $6.2 billion in Q4 2025 and then to $4.6 billion in Q1 2026, while quarterly EPS tracked from $53.0 to $50.0 and now $31.9, leaving investors weighing solid top line scale against signs of...

Fulcrum Therapeutics (FULC) has just delivered early PIONEER trial data that moved the needle, with pociredir driving meaningful fetal hemoglobin gains in sickle cell patients and setting up the stock for a very different conversation. See our latest analysis for Fulcrum Therapeutics. The PIONEER update has clearly reset expectations. Fulcrum’s 1 day share price return of 45.96% has helped drive a 30 day share price return of 70.25% and a 1 year total shareholder return of 223.94%, suggesting...

Key Insights Significant insider control over RLX Technology implies vested interests in company growth A total of 4...

AECOM ( NYSE:ACM ) has announced that it will be increasing its dividend from last year's comparable payment on the...

As the Federal Reserve meeting unfolds and major indices like the Dow Jones, S&P 500, and Nasdaq show modest gains, investors are keenly observing how potential interest rate cuts might influence market dynamics. In this environment of cautious optimism and strategic shifts, identifying undervalued stocks becomes crucial for those looking to capitalize on potential market inefficiencies.

In the last year, many KalVista Pharmaceuticals, Inc. ( NASDAQ:KALV ) insiders sold a substantial stake in the company...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Key Insights Guidewire Software to hold its Annual General Meeting on 15th of December Total pay for CEO Mike Rosenbaum...

Gulfport Energy (GPOR) has quietly outperformed many peers over the past 3 months, with the stock up more than 20% even after a recent pullback this week. See our latest analysis for Gulfport Energy. That move sits within a solid broader trend, with a 90 day share price return of about 22% and a three year total shareholder return near 200%, suggesting underlying momentum and improving sentiment around Gulfport’s long term cash generation potential. If this kind of steady compounding appeals...

Despite an already strong run, Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) shares have been powering on, with a gain...

As the U.S. stock market navigates a week marked by anticipation of the Federal Reserve's interest rate decision, major indices such as the S&P 500 have recently pulled back from record highs, reflecting investor caution amidst economic uncertainty. In this context, identifying high-growth tech stocks requires a focus on companies with robust innovation strategies and adaptability to changing market dynamics, which can potentially thrive even in volatile environments.

As the U.S. stock market navigates a period of uncertainty with investors closely watching the Federal Reserve's upcoming decision on interest rates, major indices like the S&P 500 have recently pulled back after nearing record highs. In this environment, identifying stocks trading below their intrinsic value can be particularly appealing to investors seeking potential opportunities amidst broader market fluctuations.

As the U.S. stock market experiences fluctuations with investors closely monitoring the Federal Reserve's impending decision on interest rates, many are seeking opportunities in less conventional areas of investment. Penny stocks, a term that might seem outdated but remains significant, often represent smaller or newer companies with potential for growth at accessible price points. These stocks can offer intriguing prospects when they possess strong financial health and solid fundamentals,...

Scholastic Corporation's ( NASDAQ:SCHL ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a buy right...

With its stock down 5.1% over the past three months, it is easy to disregard Lear (NYSE:LEA). However, stock prices are...

While Insight Enterprises, Inc. ( NASDAQ:NSIT ) might not have the largest market cap around , it received a lot of...